资讯

Proactive Investors9 分钟
Nordisk to downgraded by leading investment bank as growth slows and competition intensifies
UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from ...